08 Sep 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/wclc-2021--mini-oral---ascentage-pharma-announces-latest-data-of-its-investigational-bcl-2bcl-xl-inhibitor-pelcitoclax-apg-1252-combined-with-osimertinib-in-patients-with-egfr-tki-resistant-non-small-cell-lung-cancer-301371959.html